Sood AK - Search Results

1

Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer.

Ziebarth AJ, Nowsheen S, Steg AD, Shah MM, Katre AA, Dobbin ZC, Han HD, Lopez-Berestein G, Sood AK, Conner M, Yang ES, Landen CN. Ziebarth AJ, et al. Among authors: sood ak. Clin Cancer Res. 2013 Jan 1;19(1):170-82. doi: 10.1158/1078-0432.CCR-12-1045. Epub 2012 Nov 12. Clin Cancer Res. 2013. PMID: 23147994 Free PMC article.

2

Ovarian cancer genomic instability correlates with p53 frameshift mutations.

Sood AK, Skilling JS, Buller RE. Sood AK, et al. Cancer Res. 1997 Mar 15;57(6):1047-9. Cancer Res. 1997. PMID: 9067268

3

Drug resistance in ovarian cancer: from the laboratory to the clinic.

Sood AK, Buller RE. Sood AK, et al. Obstet Gynecol. 1998 Aug;92(2):312-9. doi: 10.1016/s0029-7844(98)00184-7. Obstet Gynecol. 1998. PMID: 9699774 Review.

4

Distant metastases in ovarian cancer: association with p53 mutations.

Sood AK, Sorosky JI, Dolan M, Anderson B, Buller RE. Sood AK, et al. Clin Cancer Res. 1999 Sep;5(9):2485-90. Clin Cancer Res. 1999. PMID: 10499623

5

The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma.

Shahin MS, Hughes JH, Sood AK, Buller RE. Shahin MS, et al. Among authors: sood ak. Cancer. 2000 Nov 1;89(9):2006-17. doi: 10.1002/1097-0142(20001101)89:9<2006::aid-cncr18>3.3.co;2-z. Cancer. 2000. PMID: 11064359

6

The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer.

Buller RE, Lallas TA, Shahin MS, Sood AK, Hatterman-Zogg M, Anderson B, Sorosky JI, Kirby PA. Buller RE, et al. Among authors: sood ak. Clin Cancer Res. 2001 Apr;7(4):831-8. Clin Cancer Res. 2001. PMID: 11309330

7

The paradoxical expression of maspin in ovarian carcinoma.

Sood AK, Fletcher MS, Gruman LM, Coffin JE, Jabbari S, Khalkhali-Ellis Z, Arbour N, Seftor EA, Hendrix MJ. Sood AK, et al. Clin Cancer Res. 2002 Sep;8(9):2924-32. Clin Cancer Res. 2002. PMID: 12231537

8

Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer.

Cooper BC, Ritchie JM, Broghammer CL, Coffin J, Sorosky JI, Buller RE, Hendrix MJ, Sood AK. Cooper BC, et al. Among authors: sood ak. Clin Cancer Res. 2002 Oct;8(10):3193-7. Clin Cancer Res. 2002. PMID: 12374688

9

EphA2 expression is associated with aggressive features in ovarian carcinoma.

Thaker PH, Deavers M, Celestino J, Thornton A, Fletcher MS, Landen CN, Kinch MS, Kiener PA, Sood AK. Thaker PH, et al. Among authors: sood ak. Clin Cancer Res. 2004 Aug 1;10(15):5145-50. doi: 10.1158/1078-0432.CCR-03-0589. Clin Cancer Res. 2004. PMID: 15297418

10

Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial.

Sood AK, Lush R, Geisler JP, Shahin MS, Sanders L, Sullivan D, Buller RE, Sorosky JI. Sood AK, et al. Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6080-5. doi: 10.1158/1078-0432.CCR-04-0574. Clin Cancer Res. 2004. PMID: 15447993 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,164 results

Search Page

Filters